Progesterone Capsule
Product Images NDC 69452-149

4 FDA label images from Bionpharma Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Progesterone (NDC 69452-149). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bionpharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100 mg Capsules (Image001v2)

100 mg Capsules (Image001v2)
Label for Progesterone Capsules 100 mg by Bionpharma Inc. The label includes warnings not to use if allergic to peanuts, dosage instructions, storage conditions at 20°-25°C, and packaging details for 100 count capsules. The label also states the product is Rx only and manufactured by Bionpharma at Princeton, NJ.*
FDA Label Image

200 mg Capsules (Image002v2)

200 mg Capsules (Image002v2)
Progesterone Capsules 200 mg oral capsules label by Bionpharma Inc. The label includes warnings not to use if allergic to peanuts, specifies that each capsule contains 200 mg micronized progesterone, and instructs to read accompanying directions carefully. It lists storage conditions, manufacturer information, cup points such as sealing and child safety, and a 100 count package size. The product is Rx only.*
FDA Label Image

Chemical Structure (Progesterone 01)

Chemical Structure (Progesterone 01)
Chemical structure of progesterone, the active ingredient in PROGESTERONE capsules by Bionpharma Inc. The diagram shows the molecular skeleton with characteristic ketone groups and methyl substitutions.*
FDA Label Image

Graph1 (Progesterone 02)

Graph1 (Progesterone 02)
A line graph depicting the probability of hyperplasia over time (months) on medication, comparing three groups: Conjugated Estrogens Alone, Conjugated Estrogens Plus Micronized Progesterone (cyclical), and Placebo Only. The x-axis shows time intervals (0, 12, 24, 36 months) with sample sizes at each interval, and the y-axis shows the probability of hyperplasia from 0 to 1.0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.